Exhibit 99.1
Proposed Change to Timetable for Resolution 5
Melbourne, Australia, 21 November 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, wishes to advise shareholders that there is a change to the indicative timetable for the implementation of a proposed share consolidation, that was included in the Notice of Meeting (NOM) for the Company’s Annual General Meeting (AGM).
Resolution 5 of the agenda for the AGM covers a proposed share consolidation. At tomorrow’s AGM shareholders will determine whether the resolution is passed for implementation. The new timetable is reflected below and included in the Appendix 3A.3 lodged with the ASX today.
| Key event | Updated Timetable | |
| Notification to ASX that Consolidation is approved | 22 November 2023 | |
| Last day for trading in pre-consolidated securities | 1 December 2023 | |
| Trading in consolidated securities on a deferred settlement basis commences | 4 December 2023 | |
| Record Date - Last day to register transfers on a pre-consolidation basis | 5 December 2023 | |
| First day for Company to update register and send new holding statements to security holders reflecting the change in the number of securities held | 6 December 2023 | |
| Completion of despatch of new holding statements. Deferred settlement trading ends | 12 December 2023 | |
| Normal trading starts (if Company shares are not suspended from trading at this time) | 13 December 2023 |
Authorised for release by the Board of Genetic Technologies Limited
-END-
Enquiries
Investor
Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: Adrian.mulcahy@automicgroup.com.au
| Genetic Technologies Limited | 60-66 Hanover Street |
| www.genetype.com | Fitzroy Victoria 3065 |
| info@gtglabs.com | Australia |
| ABN 17 009 212 328 | +61 3 8412 7000 |
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
Forward Looking Statements
This announcement may contain forward-looking statements about the Company’s expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
| Genetic Technologies Limited | 60-66 Hanover Street |
| www.genetype.com | Fitzroy Victoria 3065 |
| info@gtglabs.com | Australia |
| ABN 17 009 212 328 | +61 3 8412 7000 |